Experienced in Platelet Storage Pool Deficiency

Dr. Rex B. Mowat

Hematology Oncology | Hematology | Oncology

Toledo Clinic

Toledo Clinic Incorporated

2142 N Cove Blvd,

Toledo, OH

Clinical Trials:Currently Recruiting for 4 Trials

Accepting New Patients

Experienced in Platelet Storage Pool Deficiency

Toledo Clinic

Toledo Clinic Incorporated

2142 N Cove Blvd,

Toledo, OH

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rex Mowat is a Hematologist Oncology specialist and a Hematologist in Toledo, Ohio. Dr. Mowat is rated as an Experienced provider by MediFind in the treatment of Platelet Storage Pool Deficiency. His top areas of expertise are Colorectal Cancer, Chronic Lymphocytic Leukemia (CLL), Hairy Cell Leukemia (HCL), Richter Syndrome, and Bone Marrow Aspiration. Dr. Mowat is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 87 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology

Hematology

Oncology

Licenses

Internal Medicine in OH

Hospital Affiliations

Promedica Charles And Virginia Hickman Hospital

Wood County Hospital

Mercy St Vincent Medical Center

Promedica Toledo Hospital

Fulton County Health Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Buckeye Health Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN

CareSource

Cigna

First Health

INSURANCE PLAN
MEDICARE PDP
PPO

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

McLaren Health

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medical Health

Medical Mutual

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Paramount

EPO
HMO
INDEMNITY
PPO

Priority Health

Spectrum Priority Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL

SummaCare

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 19 Less Insurance Carriers -

Locations

TOLEDO CLINIC INCORPORATED
2142 N Cove Blvd, Toledo, OH 43606

Call: 419-479-5690

Other Locations

TOLEDO CLINIC INCORPORATED
718 N Macomb St, Mercy Memorial Hospital, Monroe, MI 48162

Call: 419-240-8400

TOLEDO CLINIC INCORPORATED
6450 Wheatstone Ct, Maumee, OH 43537

Call: 419-866-6200

TOLEDO CLINIC INCORPORATED
950 W Wooster St, Bowling Green, OH 43402

Call: 419-373-7696

TOLEDO CLINIC INCORPORATED
4235 Secor Rd, Toledo, OH 43623

Call: 419-479-5398

TOLEDO CLINIC INCORPORATED
4126 N Holland Sylvania Rd, Toledo, OH 43623

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

86 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Procedure, Biological, Drug, Other

Study Drugs: Obinutuzumab, Venetoclax

Study Phase: Phase 3

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bevacizumab, Osimertinib

Study Phase: Phase 3

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: October 14, 2025

Intervention Type: Drug

Study Drugs: ALT-803, Bacillus Calumette-Guerin

Study Phase: Phase 2/Phase 3

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Other, Radiation, Procedure, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Drug, Procedure

Study Drugs: Cytarabine, Daunorubicin, Uproleselan

Study Phase: Phase 2/Phase 3

A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma

Enrollment Status: Completed

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug, Radiation

Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride

Study Phase: Phase 3

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)

Enrollment Status: Active_not_recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Cabozantinib S-malate

Study Phase: Phase 3

Genomically-Guided Treatment Trial in Brain Metastases

Enrollment Status: Suspended

Publish Date: October 08, 2025

Intervention Type: Drug

Study Drugs: Abemaciclib, Paxalisib, Entrectinib

Study Phase: Phase 2

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Suspended

Publish Date: October 07, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 30, 2025

Intervention Type: Radiation

Study Phase: Phase 3

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 26, 2025

Intervention Type: Drug, Biological, Procedure

Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate

Study Phase: Phase 2

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Enrollment Status: Active_not_recruiting

Publish Date: September 25, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab

Study Phase: Phase 2

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Biological, Other

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate

Study Phase: Phase 2

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib, Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax

Study Phase: Phase 3

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Other

Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab

Study Phase: Phase 2

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 3

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Other, Procedure

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Procedure, Drug

Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 2

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 16, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide

Study Phase: Phase 3

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate

Study Phase: Phase 3

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial

Enrollment Status: Completed

Publish Date: September 15, 2025

Intervention Type: Drug

Study Drugs: Elacestrant, Standard of Care

Study Phase: Phase 3

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Biological, Drug

Study Drugs: Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab

Study Phase: Phase 2

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone

Study Phase: Phase 2

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Atezolizumab, Bevacizumab, Carboplatin, Cetuximab, Cisplatin, Docetaxel

Study Phase: Phase 2/Phase 3

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab

Study Phase: Phase 2

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Enrollment Status: Terminated

Publish Date: August 28, 2025

Intervention Type: Drug

Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim

Study Phase: Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: August 26, 2025

Intervention Type: Drug

Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant

Study Phase: Phase 2

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies

Enrollment Status: Active_not_recruiting

Publish Date: August 07, 2025

Intervention Type: Drug

Study Drugs: Brentuximab vedotin, Pembrolizumab

Study Phase: Phase 2

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Enrollment Status: Active_not_recruiting

Publish Date: July 30, 2025

Intervention Type: Other, Drug

Study Drugs: Temozolomide, Veliparib

Study Phase: Phase 2/Phase 3

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 20, 2025

Intervention Type: Biological, Radiation

Study Drug: Cetuximab

Study Phase: Phase 3

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Enrollment Status: Completed

Publish Date: July 03, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab

Study Phase: Phase 2

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)

Enrollment Status: Completed

Publish Date: June 18, 2025

Intervention Type: Other, Drug

Study Drugs: Clobetasol propionate, Regorafenib

Study Phase: Phase 2

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Drug

Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin

Study Phase: Phase 2

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)

Enrollment Status: Active_not_recruiting

Publish Date: June 10, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide

Study Phase: Phase 1/Phase 2

Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases

Enrollment Status: Completed

Publish Date: May 16, 2025

Intervention Type: Other, Drug

Study Drugs: Cisplatin, Veliparib

Study Phase: Phase 2

View 46 Less Clinical Trials

26 Total Publications

Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance).

Journal: The oncologist

Published: May 16, 2021

View All 26 Publications

Similar Doctors

Advanced in Platelet Storage Pool Deficiency

Dr. Suman L. Sood

Hematology | Hematology Oncology | Oncology

Advanced in Platelet Storage Pool Deficiency

Dr. Suman L. Sood

Hematology | Hematology Oncology | Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr,

Ann Arbor, MI

(42.8 miles away)

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Suman Sood is a Hematologist and a Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Sood is rated as a Distinguished provider by MediFind in the treatment of Platelet Storage Pool Deficiency. Her top areas of expertise are Hemophilia A, Deep Vein Thrombosis, Hemophilic Arthropathy, Von Willebrand Disease (VWD), and Bone Marrow Aspiration. Dr. Sood is currently accepting new patients.

Distinguished in Platelet Storage Pool Deficiency

Dr. Carter R. Bishop

Hematology | Oncology

Distinguished in Platelet Storage Pool Deficiency

Dr. Carter R. Bishop

Hematology | Oncology

University Physician Group

4100 John R St,

Detroit, MI

(54.4 miles away)

800-527-6266

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Carter Bishop is a Hematologist and an Oncologist in Detroit, Michigan. Dr. Bishop is rated as an Advanced provider by MediFind in the treatment of Platelet Storage Pool Deficiency. His top areas of expertise are Sickle Cell Disease, Gray Platelet Syndrome, Bernard-Soulier Syndrome, and Platelet Storage Pool Deficiency. Dr. Bishop is currently accepting new patients.

Advanced in Platelet Storage Pool Deficiency

Dr. Drew R. Oostra

Hematology Oncology | Hematology | Oncology

Advanced in Platelet Storage Pool Deficiency

Dr. Drew R. Oostra

Hematology Oncology | Hematology | Oncology

Promedica Central Physicians

2109 Hughes Dr, Suite 450,

Toledo, OH

(0.2 miles away)

419-291-2003

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Drew Oostra is a Hematologist Oncology specialist and a Hematologist in Toledo, Ohio. Dr. Oostra is rated as an Advanced provider by MediFind in the treatment of Platelet Storage Pool Deficiency. His top areas of expertise are Pulmonary Embolism, Deep Vein Thrombosis, Glanzmann Thrombasthenia, and Bernard-Soulier Syndrome. Dr. Oostra is currently accepting new patients.

VIEW MORE PLATELET STORAGE POOL DEFICIENCY DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mowat's expertise for a condition

ConditionClose